Apigenin shows up in a growing body of animal and cell research on blood sugar regulation, insulin secretion, and metabolic health, often discussed alongside its anti-inflammatory and PPAR-related mechanisms. None of this has been tested in a human clinical trial for blood sugar specifically, so any claim that apigenin “helps blood sugar” in people is currently unproven. Here’s what the preclinical evidence actually shows, and where the real uncertainty lies.
Key Takeaways
- In diabetic rat models, apigenin lowered blood glucose, improved insulin resistance markers, and reduced markers of vascular inflammation compared to untreated diabetic controls.
- In mice, apigenin acted on PPAR-gamma, a nuclear receptor targeted by prescription diabetes drugs like pioglitazone, and unlike rosiglitazone it did not cause significant weight gain [2].
- A 2024 study found apigenin increases glucose-stimulated insulin secretion from pancreatic islet cells through a PKA-MEK kinase signaling pathway distinct from how sulfonylurea diabetes medications work.
- All of this evidence comes from isolated cells, isolated pancreatic islets, or rodent models: there is no published human trial measuring apigenin’s effect on blood glucose, HbA1c, or insulin sensitivity.
- In lab enzyme studies, apigenin inhibited CYP1A2, CYP2C9, and CYP3A4 enzymes, which could matter in theory for anyone on prescription diabetes medications metabolized through those pathways [4][5][6][7][8]a conversation for a physician, not a supplement label.
What the Animal Research Actually Found
A 2016 study induced type 2 diabetes in rats using a high-fat diet combined with streptozotocin, then treated one group with apigenin. Compared to untreated diabetic rats, the apigenin group showed significantly lower blood glucose, lower serum lipids, lower markers of oxidative stress (malondialdehyde), and improved insulin resistance index. The same study found apigenin improved impaired glucose tolerance and reduced markers of vascular inflammation (ICAM-1) in blood vessel lining cells exposed to high fatty-acid conditions.[1] This is a single animal study, not a replication series, and it used a specific diabetes-induction model that doesn’t map directly onto how type 2 diabetes develops in humans over years.
A separate line of research looked at apigenin’s effect on high-fat-diet-induced obese mice over 16 weeks of dietary supplementation. Apigenin-supplemented mice showed lower plasma free fatty acids, lower total cholesterol, less hepatic steatosis (fatty liver), and reduced activity of liver enzymes involved in making new glucose and storing fat, without a change in body weight or food intake in that particular study. The mechanism proposed was altered expression of genes controlling fatty acid oxidation and lipid storage in the liver, which indirectly affects whole-body insulin sensitivity.
The PPAR-Gamma Connection
PPAR-gamma is a nuclear receptor that regulates fat cell development, glucose uptake, and insulin sensitivity. It’s the target of the thiazolidinedione class of diabetes drugs (pioglitazone, and the discontinued rosiglitazone), which activate PPAR-gamma to improve insulin sensitivity but commonly cause weight gain, fluid retention, and increased fracture risk. A 2016 study found that apigenin acts as a PPAR-gamma modulator: it binds and partially activates the receptor, which blocked a key inflammatory signaling step (p65/NF-kB translocation) and shifted immune cells in fat tissue toward a less-inflammatory state. In that mouse model, apigenin reduced liver and muscle fat accumulation and lowered liver enzyme markers without the weight gain associated with full PPAR-gamma agonist drugs.[2]
Research note: In alloxan-induced diabetic mice, 0.78 mg/kg apigenin for 10 days raised serum insulin and thyroid hormones and lowered blood glucose [10].
This is a meaningful mechanistic finding, because “partial PPAR-gamma modulation without the side-effect profile of full agonists” is an active area of pharmaceutical research in its own right. It does not mean apigenin is a safe or effective substitute for a prescribed diabetes medication: the comparison is at the level of a shared molecular target in mice, not clinical outcomes in people.
Apigenin and Insulin Secretion Directly
A 2024 study went further and tested apigenin’s direct effect on insulin-secreting pancreatic islet cells, isolated from mice, and on diabetic rats in vivo. Apigenin dose-dependently increased insulin secretion at high glucose concentrations, working through a PKA and MEK kinase signaling pathway rather than the K-ATP channel mechanism that sulfonylurea drugs (like glimepiride) use. In the live animal portion of the study, apigenin improved glucose tolerance and raised glucose-stimulated plasma insulin levels in diabetic rats, and chronic treatment lowered their blood glucose.[3] Because the mechanism differs from existing insulin secretagogue drugs, this is the kind of finding that generates legitimate pharmaceutical research interest, but again, it’s isolated islets and rodents, not a human pancreas.
What This Doesn’t Mean
Three separate preclinical mechanisms (direct glucose/lipid improvement in diabetic rats, PPAR-gamma modulation, and direct insulin secretagogue activity in islet cells) is a genuinely interesting convergence of evidence for a single flavonoid. It is not the same thing as a demonstrated blood-sugar benefit in humans. No published trial has given apigenin supplements to people with prediabetes or type 2 diabetes and measured fasting glucose, HbA1c, or insulin sensitivity as an outcome. The doses used in the animal studies above (the 2016 rat study used 50 or 100 mg per kilogram by gavage for 6 weeks) [1] don’t translate directly to a human-equivalent dose without pharmacokinetic modeling that hasn’t been published for this specific use case.
There’s also a real interaction consideration that has nothing to do with whether apigenin helps or doesn’t help blood sugar: in lab studies apigenin inhibited CYP1A2, CYP2C9, and CYP3A4, liver enzymes that metabolize a number of prescription drugs, including some used in diabetes management. These are test-tube results, not demonstrated interactions in people [4][5][6][7][8]. Anyone on glucose-lowering medication who is considering an apigenin supplement should raise it with their prescribing physician specifically because of this interaction risk, independent of any direct blood-sugar effect apigenin itself might have.
The human data that do exist involve chamomile tea, not apigenin. A review describes a single-blind randomised trial in diabetic patients in which chamomile tea three times a day significantly decreased HbA1c, insulin, cholesterol, triglycerides and LDL. Tea contains many compounds, so this cannot be credited to apigenin [9].
Bottom Line
Apigenin has three separate, mechanistically plausible pathways connecting it to blood sugar regulation in preclinical research: direct glucose/lipid improvement in diabetic rodent models, PPAR-gamma modulation without the typical side-effect profile of drug-class PPAR-gamma agonists, and direct stimulation of insulin secretion from pancreatic islet cells through a novel signaling pathway. All of it is animal and cell research. No human trial has tested apigenin for blood sugar, glucose tolerance, or diabetes management, and anyone on prescription glucose-lowering medication should talk to their doctor before adding apigenin because apigenin inhibited drug-metabolizing enzymes in lab studies, not because [4][5] the blood-sugar evidence itself is settled either way.
Frequently Asked Questions
Does apigenin lower blood sugar?
Apigenin has lowered blood glucose and improved insulin resistance markers in diabetic rat and mouse studies through several mechanisms, including PPAR-gamma modulation and direct stimulation of insulin secretion from pancreatic islet cells. No human clinical trial has tested this, so it remains an unproven effect in people.
Is apigenin safe to take with diabetes medication?
In lab studies, apigenin inhibited CYP1A2, CYP2C9, and CYP3A4, liver enzymes that metabolize a number of prescription drugs, including some diabetes medications. These are test-tube results, not demonstrated interactions in people, but anyone on glucose-lowering medication should still discuss apigenin with their prescribing physician before use [4][5][6][7][8].
How does apigenin affect insulin secretion?
A 2024 study found apigenin increases glucose-stimulated insulin secretion from isolated pancreatic islet cells through a PKA-MEK kinase signaling pathway, distinct from how sulfonylurea diabetes drugs work. This was tested in isolated mouse islets and diabetic rats, not humans.
References
- Ren B et al. Apigenin and naringenin regulate glucose and lipid metabolism, and ameliorate vascular dysfunction in type 2 diabetic rats. European Journal of Pharmacology (2016). PMID 26801071
- Feng X et al. Activation of PPARγ by a Natural Flavonoid Modulator, Apigenin Ameliorates Obesity-Related Inflammation Via Regulation of Macrophage Polarization. EBioMedicine (2016). PMID 27374313
- Shahab F et al. Apigenin potentiates glucose-stimulated insulin secretion through the PKA-MEK kinase signaling pathway independent of K-ATP channels. Biomedicine & Pharmacotherapy (2024). PMID 38906017
- Fei Lin et al. Inhibitory effect of Selaginella doederleinii hieron on human cytochrome P450. Frontiers in Pharmacology (2023). PMID 36874034
- Wang Z et al. Inhibitory Effect of Apigenin on Losartan Metabolism and CYP2C9 Activity in vitro. Pharmacology (2016). PMID 27287328
- Si D et al. Mechanism of CYP2C9 inhibition by flavones and flavonols. Drug metabolism and disposition: the biological fate of chemicals (2009). PMID 19074529
- Shimada H et al. Differential mechanisms for the inhibition of human cytochrome P450 1A2 by apigenin and genistein. Journal of biochemical and molecular toxicology (2010). PMID 20806393
- Kondža M et al. Characterization of the CYP3A4 Enzyme Inhibition Potential of Selected Flavonoids. Molecules (Basel, Switzerland) (2021). PMID 34069400
- Bayliak MM et al. Chamomile as a potential remedy for obesity and metabolic syndrome. EXCLI journal (2021). PMID 34602925
- Sunanda Panda et al. Apigenin (4‘,5,7-trihydroxyflavone) regulates hyperglycaemia, thyroid dysfunction and lipid peroxidation in alloxan-induced diabetic mice. Journal of Pharmacy and Pharmacology (2007). PMID 17976266
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
